Cargando…

Carbimazole-induced cholestatic hepatitis in Graves’ disease

Antithyroid medications are one of the treatment options for Graves’ disease. Carbimazole is widely used as the drug of choice, except in pregnancy, where propythiouracil is preferred by many. It is generally well-tolerated. Its side-effects include allergy, upper gastrointestinal upset, a rare occu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kota, Sunil K., Meher, Lalit K., Kota, Siva K., Jammula, Sruti, Modi, Kirtikumar D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683215/
https://www.ncbi.nlm.nih.gov/pubmed/23776913
http://dx.doi.org/10.4103/2230-8210.109660
_version_ 1782273473392934912
author Kota, Sunil K.
Meher, Lalit K.
Kota, Siva K.
Jammula, Sruti
Modi, Kirtikumar D.
author_facet Kota, Sunil K.
Meher, Lalit K.
Kota, Siva K.
Jammula, Sruti
Modi, Kirtikumar D.
author_sort Kota, Sunil K.
collection PubMed
description Antithyroid medications are one of the treatment options for Graves’ disease. Carbimazole is widely used as the drug of choice, except in pregnancy, where propythiouracil is preferred by many. It is generally well-tolerated. Its side-effects include allergy, upper gastrointestinal upset, a rare occurrence of granulocytosis, and others. Hepatitis is another rare, but serious side-effect. We report a healthy 30-year-old male patient with Graves’ disease, who developed cholestatic jaundice after Carbimazole therapy for four months. He made a full recovery after the drug was discontinued. An idiosyncratic mechanism seemed likely.
format Online
Article
Text
id pubmed-3683215
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-36832152013-06-17 Carbimazole-induced cholestatic hepatitis in Graves’ disease Kota, Sunil K. Meher, Lalit K. Kota, Siva K. Jammula, Sruti Modi, Kirtikumar D. Indian J Endocrinol Metab Case Report Antithyroid medications are one of the treatment options for Graves’ disease. Carbimazole is widely used as the drug of choice, except in pregnancy, where propythiouracil is preferred by many. It is generally well-tolerated. Its side-effects include allergy, upper gastrointestinal upset, a rare occurrence of granulocytosis, and others. Hepatitis is another rare, but serious side-effect. We report a healthy 30-year-old male patient with Graves’ disease, who developed cholestatic jaundice after Carbimazole therapy for four months. He made a full recovery after the drug was discontinued. An idiosyncratic mechanism seemed likely. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3683215/ /pubmed/23776913 http://dx.doi.org/10.4103/2230-8210.109660 Text en Copyright: © Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kota, Sunil K.
Meher, Lalit K.
Kota, Siva K.
Jammula, Sruti
Modi, Kirtikumar D.
Carbimazole-induced cholestatic hepatitis in Graves’ disease
title Carbimazole-induced cholestatic hepatitis in Graves’ disease
title_full Carbimazole-induced cholestatic hepatitis in Graves’ disease
title_fullStr Carbimazole-induced cholestatic hepatitis in Graves’ disease
title_full_unstemmed Carbimazole-induced cholestatic hepatitis in Graves’ disease
title_short Carbimazole-induced cholestatic hepatitis in Graves’ disease
title_sort carbimazole-induced cholestatic hepatitis in graves’ disease
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683215/
https://www.ncbi.nlm.nih.gov/pubmed/23776913
http://dx.doi.org/10.4103/2230-8210.109660
work_keys_str_mv AT kotasunilk carbimazoleinducedcholestatichepatitisingravesdisease
AT meherlalitk carbimazoleinducedcholestatichepatitisingravesdisease
AT kotasivak carbimazoleinducedcholestatichepatitisingravesdisease
AT jammulasruti carbimazoleinducedcholestatichepatitisingravesdisease
AT modikirtikumard carbimazoleinducedcholestatichepatitisingravesdisease